- Home
- JANX vs QNST Comparison
JANX vs QNST Comparison
Compare JANX & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | QNST |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | JANX | QNST |
|---|---|---|
| Price | $17.54 | $17.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 6 |
| Target Price | ★ $33.81 | $22.80 |
| AVG Volume (30 Days) | ★ 751.0K | 730.1K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1650.00 |
| EPS | N/A | ★ 1.40 |
| Revenue | $10,000,000.00 | ★ $282,140,000.00 |
| Revenue This Year | $194.24 | $15.97 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | ★ N/A | $12.20 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $10.29 |
| 52 Week High | $35.34 | $22.29 |
Technical Indicators
Market Signals| Indicator | JANX | QNST |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 60.14 |
| Support Level | $15.90 | $11.50 |
| Resistance Level | $19.16 | $18.02 |
| Average True Range (ATR) | 0.83 | 0.53 |
| MACD | 0.07 | 0.19 |
| Stochastic Oscillator | 48.72 | 93.63 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. The company operates as one reportable segment. The company generates majority of revenue from United States. The company's products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and Cloud Control Media.